Table 1.
Characteristic | TCGA Discovery Dataset (n = 330) | TCGA Validation Dataset (n = 196) | ||
---|---|---|---|---|
No. | % | No. | % | |
Status | ||||
Alive | 258 | 78.2 | 109 | 55.6 |
Dead | 72 | 21.8 | 87 | 44.4 |
Sex | ||||
Male | 214 | 64.8 | 127 | 64.8 |
Female | 116 | 35.2 | 69 | 35.2 |
Tumor stage | ||||
Stages I and II | 222 | 67.3 | 98 | 50.0 |
Stages III and IV | 108 | 32.7 | 98 | 50.0 |
Age, years | ||||
Median | 60 | — | 62 | — |
Range | 26–90 | — | 34–85 | — |
Non-silent mutations in VHL (Von Hippel–Lindau Tumor Suppressor) | ||||
Yes | 150 | 45.5 | — | — |
No | 180 | 54.5 | — | — |
Non-silent mutations in PBRM1 (Polybromo 1) | ||||
Yes | 128 | 38.8 | — | — |
No | 202 | 61.2 | — | — |
Non-silent mutations in TTN (Titin) | ||||
Yes | 58 | 17.6 | — | — |
No | 272 | 82.4 | — | — |
Non-silent mutations in SETD2 (SET Domain Containing 2) | ||||
Yes | 39 | 11.8 | — | — |
No | 291 | 88.2 | — | — |
Non-silent mutations in BAP1 (BRCA1 Associated Protein 1) | ||||
Yes | 29 | 8.8 | — | — |
No | 301 | 91.2 | — | — |